Key result
Human monoclonal antibodies targeting domain A of the HCV E2 glycoprotein do not neutralize HCV pseudoparticle infection and do not interfere with the neutralizing activity of antibodies targeting domains B and C.
Population
HCV retroviral pseudotype particles (HCVpp) and Huh-7 cells
Comparison
Human monoclonal antibodies targeting HCV E2… vs Absence of domain A HMAbs; normal pH vs acid…
Design
Preclinical
Authors
Loading...
Non-neutralizing domain A antibodies do not block B/C neutralization; leaves open their inclusion or avoidance in HCV vaccine design.
Domain A of HCV E2 glycoprotein contains nonneutralizing epitopes that do not interfere with neutralizing antibodies, suggesting their induction is not a central issue for HCV vaccine design.
Keck et al. (2005) studied Hepatitis C Virus (HCV) infection. Human monoclonal antibodies (HMAbs) to HCV E2 domain A vs. Domain B and C HMAbs, or no antibody was evaluated on Neutralization of HCV retroviral pseudotype particle (HCVpp) infection on Huh-7 cells. Human monoclonal antibodies targeting domain A of the HCV E2 glycoprotein do not neutralize HCV pseudoparticle infection and do not interfere with the neutralizing activity of antibodies targeting domains B and C.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: